Gheuens Sarah 4

What Happened
Sarah Gheuens, a director of Viridian Therapeutics (VRDN), was granted a derivative award of 32,341 shares on July 1, 2026. The grant shows $0.00 paid at acquisition (i.e., no cash consideration reported) and is reported as a derivative/option award rather than an immediate stock purchase.

Key Details

• Transaction date: 2026-07-01; Form 4 filed: 2026-07-02 (timely filing).
• Transaction type/code: Grant/Award (A) of 32,341 derivative shares at $0.00.
• Vesting: The option vests in full upon the earlier of (i) July 1, 2027 or (ii) the issuer’s 2027 annual meeting of stockholders, subject to Ms. Gheuens’ continued service on the board (per footnote).
• Shares owned after transaction: Not disclosed in this filing.
• No exercise or sale occurred — this is a grant of an option/award, not a cash transaction or open-market trade.

Context
This is a typical director compensation award: an option-style grant that vests contingent on continued board service and a future date/event. Such grants compensate and retain directors and do not represent an immediate buy or sell of company stock. For retail investors, awards are informative about board compensation but are not a direct bullish or bearish market action like a purchase or sale.